Vasopressin-Rezeptor-Antagonisten: Aktueller Stellenwert in der Therapie der Herzinsuffizienz

Schlüsselwörter

Vasopressin - Vaptane - Hyponatriämie - Herzinsuffizienz

Keywords

vasopressin - vaptans - hyponatremia - heart failure

• Literatur

• 1 Abraham WT, Aranda JM, Boehmer JP et al. Rationale and Design of the Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation (THE BALANCE) Study. Clin Transl Sci 2010; 3: 249-253
• 2 Abraham WT, Shamshirsaz AA, McFann K et al. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol 2006; 47: 1615-1621
• 3 Albright JD, Reich MF, Delos Santos EG et al. 5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors. J Med Chem 1998; 41: 2442-2444
• 4 Ali ZA, Callaghan CJ, Lim E et al. Remote ischemic preconditioning reduces myocardial and renal injury after elective abdominal aortic aneurysm repair: a randomized controlled trial. Circulation 2007; 116: I98-105
• 5 Aronson D, Verbalis JG, Mueller M et al. Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: the DILIPO study. Eur J Heart Fail 13: 327-336
• 6 Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm 2007; 13: 9-20
• 7 Baylis PH. Osmoregulation and control of vasopressin secretion in healthy humans. Am J Physiol 1987; 253: R671-678
• 8 Costello-Boerrigter LC, Boerrigter G, Burnett JC et al. Pharmacology of vasopressin antagonists. Heart Fail Rev 2009; 14: 75-82
• 9 Finley JJt, Konstam MA, Udelson JE. Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia. Circulation 2008; 118: 410-421
• 10 Gassanov N, Jankowski M, Danalache B et al. Arginine vasopressin-mediated cardiac differentiation: insights into the role of its receptors and nitric oxide signaling. J Biol Chem 2007; 282: 11255-11265
• 11 Gassanov N, Semmo N, Semmo M et al. Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH). Eur J Clin Pharmacol 67: 333-346
• 12 Ghali JK, Orlandi C, Abraham WT. The efficacy and safety of lixivaptan in outpatients with heart failure and volume overload: results of a multicentre, randomized, double-blind, placebo-controlled, parallel-group study. Eur J Heart Fail 2012; 14: 642-651
• 13 Gheorghiade M, Gattis WA, O'Connor CM et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004; 291: 1963-1971
• 14 Gheorghiade M, Niazi I, Ouyang J et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003; 107: 2690-2696
• 15 Gibbons RJ, Balady GJ, Bricker JT et al. ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol 2002; 40: 1531-1540
• 16 Goldsmith SR, Elkayam U, Haught WH et al. Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study. J Card Fail 2008; 14: 641-647
• 17 Holmes CL, Landry DW, Granton JT. Science review: Vasopressin and the cardiovascular system part 1 – receptor physiology. Crit Care 2003; 7: 427-434
• 18 Hoppe U, Erdmann E. Für die Kommission Klinische Kardiologie. Leitlinien zur Therapie der chronischen Herzinsuffizienz. Hrsg. vom Vorstand der Deutschen Gesellschaft für Kardiolgie – Herz- und Kreislaufforschung. Bearbeitet im Auftrag der Kommission für Klinische Kardiologie in Zusammenarbeit mit der Arzneimittelkommission der Deutschen Ärzteschaft. Z Kardiol 2001; 90: 218-237
• 19 Konstam MA, Gheorghiade M, Burnett Jr JC et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007; 297: 1319-1331
• 20 Lehrich RW, Greenberg A. When is it appropriate to use vasopressin receptor antagonists?. J Am Soc Nephrol 2008; 19: 1054-1058
• 21 Nakamura Y, Haneda T, Osaki J et al. Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V(1A) receptor. Eur J Pharmacol 2000; 391: 39-48
• 22 Plosker GL. Tolvaptan. Drugs 2010; 70: 443-454
• 23 Rangasetty UC, Gheorghiade M, Uretsky BF et al. Tolvaptan: a selective vasopressin type 2 receptor antagonist in congestive heart failure. Expert Opin Investig Drugs 2006; 15: 533-540
• 24 Robertson GL, Shelton RL, Athar S. The osmoregulation of vasopressin. Kidney Int 1976; 10: 25-37
• 25 Sawyer WH, Pang PK, Seto J et al. Vasopressin analogs that antagonize antidiuretic responses by rats to the antidiuretic hormone. Science 1981; 212: 49-51
• 26 Schweiger TA, Zdanowicz MM. Vasopressin-receptor antagonists in heart failure. Am J Health Syst Pharm 2008; 65: 807-817
• 27 Soupart A, Gross P, Legros JJ et al. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clin J Am Soc Nephrol 2006; 1: 1154-1160
• 28 Swaab DF, Nijveldt F, Pool CW. Distribution of oxytocin and vasopressin in the rat supraoptic and paraventricular nucleus. J Endocrinol 1975; 67: 461-462
• 29 Udelson JE, McGrew FA, Flores E et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol 2007; 49: 2151-2159
• 30 Udelson JE, Orlandi C, Ouyang J et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol 2008; 52: 1540-1545
• 31 Udelson JE, Smith WB, Hendrix GH et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001; 104: 2417-2423
• 32 Yamamura Y, Ogawa H, Yamashita H et al. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol 1992; 105: 787-791
• 33 Yatsu T, Tomura Y, Tahara A et al. Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure. Eur J Pharmacol 1999; 376: 239-246